Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: IVIg supplementation in recipients of BCMA-directed TCEs for myeloma may be associated with improved outcomes, including favorable infection-free and overall survival; extramedullary and high-risk disease confer poor outcomes.”

“Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma”

Authors: Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi Shah, Carolina Schinke et al.

Myeloma Paper of the Day, April 24th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.